Loading stock data…
AGEN
$3.30-0.09 (-2.65%)
Pre-Market$3.29-0.01 (-0.30%)· Last close Jun 12
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agenus Inc. in the Healthcare sector is trading at $3.30. Wall Street consensus targets $15.50 (2 analysts), implying a +369.7% move over the next 12 months. The stock is currently near its 52-week low of $2.71, remaining 12.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +369.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $33.74M↓ | $34.20M↑ | $30.23M↑ | $25.69M↑ | $24.07M |
| Gross Profit | $21.91M↓ | $26.69M↑ | $6.00M↑ | -$1.26M↓ | $2.41M |
| Operating Income | $15.05M↑ | $14.40M↑ | -$4.86M↑ | -$16.78M↓ | -$13.31M |
| Net Income | $39.23M↑ | -$10.58M↓ | $63.91M↑ | -$27.95M↓ | -$25.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identificati...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.20%
Volume
Today's trading volume
505,335
Recent News
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early survival signals translate into a pivotal win.
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.